Growth Opportunities Vanda is a mid to large biotech with recent product launches and regulatory milestones including NEREUS (tradipitant) for motion-induced vomiting now commercially available in the US, signaling potential cross-sell opportunities for supportive therapies, patient access programs, and physician education initiatives.

Therapy Pipeline Active development in rare disease space with CMT2S antisense therapy VCA-894A and Rare Pediatric Disease designation, presenting channels for strategic partnerships, investigator-initiated studies, and potential co-development or in-licensing discussions with specialty distributors.

Clinical & FDA Align Ongoing FDA-engagement around CMT2S program indicates receptivity to collaborative trial design, regulatory consulting, and external milestone-based funding options that could align with partner-portfolio financing models.

Strategic Events Participation in industry summits and investor-focused events (Mind, Muscle & Vision Summit, B. Riley Securities events) creates opportunities for targeted outreach to neuro-musculoskeletal and ophthalmic specialists, as well as funding partners and potential distributors.

Financial Position Moderate revenue scale with recent equity and investment signals; potential for co-spend on rare disease programs, companion diagnostic collaborations, and contract manufacturing or process optimization services to support manufacturing scale as the portfolio grows.